CSL Behring's Hemophilia B Drug May Have Dosing Advantage
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Idelvion, a long-acting recombinant albumin fusion protein, with potential to provide up to 14-day dosing; Biogen's Alprolix is dosed once weekly.
You may also be interested in...
Novo Nordisk’s Hemophilia B Drug Faces Safety Scrutiny By US FDA Panel
Novo’s long-acting coagulation Factor IX showed polyethylene glycol (PEG) accumulation in the choroid plexus of animals, potentially raising a neurological safety issue when used in humans, FDA says ahead of Blood Products Advisory Committee review.
Biogen Plays It Safe With Pricing Of Hemophilia Drug Alprolix
Biogen Idec will price its new hemophilia B drug Alprolix on par with older medicines like Pfizer’s Benefix on an annual basis despite the drug’s dosing advantage. The decision comes as high drug prices have come under increased scrutiny from payers and U.S. legislators.
Updated: ImprimisRx's Approval And Superiority Claims For Compounded Drug Draw FDA Warning
The company known for compounding versions of Martin Shkreli’s Daraprim and Allergan’s Restasis is hit with a warning letter for promotions in professional periodicals about its compounded eye drop.